Jefferies Reiterates Buy Rating on Tandem Diabetes Care (TNDM)

July 8, 2024 12:25 PM EDT Send to a Friend
Jefferies analyst Matthew Taylor reiterated a Buy rating and $60.00 price target on Tandem Diabetes Care (NASDAQ: TNDM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login